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The menopause mess 
 
Susan R. Johnson, MD, MS1,2 
 
Our beliefs about menopause have 
been challenged by a series of 
randomized clinical trials, including the 
Women’s Health Initiative (WHI), which 
have contradicted the results of 
observational studies which suggested 
hormone treatment as a “prevent all” for 
coronary heart disease, as well as 
several other common chronic diseases. 
 
WHI has shown that estrogen plus 
progestin (E+P) has a different risk 
profile than estrogen only.  Women in 
the study (who begin E+P at least 5 
years after the final period) had 
increased risk for breast cancer, stroke, 
coronary heart disease, and pulmonary 
embolism.  Follow up analyses have 
shown that the risk for breast cancer 
declines, and returns to baseline within 
2 years of discontinuing E+P.  Estrogen 
only, on the other hand, appears not to 
increase the risks of either heart disease 
or breast cancer, and there is some 
evidence that if started early in the 
menopause heart disease risk may be 
decreased. 
 
The message, based on the WHI 
analyses to date, remains the same: 
while hormone treatment is the most 
effective way to treat vasomotor 
symptoms, its use for prevention of 
chronic disease in women over 60 is not 
recommended.1 Because our 
understanding of the risks and benefits 
of hormone treatment remains a work in 
progress, clinicians should monitor 
future research. Two resources are the 
North American Menopause Society 
(NAMS)(http://www.menopause.org/), 
especially the position statements on 
menopause treatments, and the WHI 
(http://www.whi.org/), which includes 
summaries of new findings. 
 
In the last decade we have also learned 
more about the menopause transition, 
the phase in which women move from 
reproductive age ovarian functioning to 
the final menstrual period. The Study of 
Women’s Health Across the Nation 
(SWAN), is in its 11th year of data 
collection from a multi-ethnic cohort of 
over 3,000 women who were in their 
early 40’s at the time the study began. 
SWAN seeks to better characterize the 
hormonal and symptom patterns of the 
transition, find a marker that will predict 
the final menstrual period, and 
determine factors that predict healthy 
aging. 
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Several findings are of interest to 
clinicians. Vasomotor symptoms 
commonly begin in the early transition, 
when women are still having regular 
menstrual periods; the rate of hot 
flashes doubles in the late transition and 
remains at the same level into the 
postmenopause.  For a significant 
minority, hot flashes continue at least 
into the 60’s. Depressive symptoms 
have been shown in other studies to 
increase during the menopause 
transition. SWAN showed, for the first 
time, that there is also an increase in the 
diagnosis of major depressive disorder 
at that time.2  SWAN has confirmed a 
decline in sexual desire beginning with 
the early transition. Cognitive function 
appears to be temporarily affected by 
the transition.  Individuals taking 
cognitive tests repeatedly over time 
usually demonstrate a steady rate of 
improvement. Women in the transition 
demonstrate a slower rate of 
improvement, which then reverts to the 
normal rate in the post menopause.3 
Finally, SWAN has found an increase in 
occasional urinary incontinence during 
this phase.4 
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